Evidence map›Paper›PMID 25756195›Full record

ArticleAIDS (London, England)2015

Multilayered HIV-1 gag-specific T-cell responses contribute to slow progression in HLA-A*30-B*13-C*06-positive patients.

Hui Zhang, Xiaoxu Han, Bin Zhao, Minghui An, Zhe Wang, Fanming Jiang, Junjie Xu, Zining Zhang, Tao Dong, Hong Shang

Open access · hybridAbstract read
In one paragraph

Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Hui ZhangaKey Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang bCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou cCenter for Disease Control and Prevention of Henan Province, Zhengzhou, China dMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford University, Oxford, UK. *Hui Zhang and Hong Shang contributed equally to the writing of this article.
Xiaoxu Han
Bin Zhao
Minghui An
Zhe Wang
Fanming Jiang
Junjie Xu
Zining Zhang
Tao Dong
Hong Shang
China Medical University · CNNational Health and Family Planning Commission · CNHenan Provincial Center for Disease Control and Prevention · CNMRC Human Immunology Unit · GB

Funding

Medical Research Council G0600520Medical Research Council G1001046Medical Research Council MR/L018942/1
6 · The paper itself

Abstract

objectiveThe HLA-A30-B13-C06 haplotype is reported to be associated with slow disease progression in the HIV-1-infected Northern Han Chinese population, but the mechanism remains unknown.

designGag-specific T-cell responses and gag sequencing were performed in nine B' clade HIV-1-infected HLA-A30-B13-C06-positive slow progressors to understand HLA-associated viral control.

methodsInterferon-γ ELISPOT assays were performed to determine the Gag-specific T-cell responses and cross-reactivity to variant peptides. Longitudinal HIV-1 gag sequencing was performed at the clonal level.

resultsThe overlapping peptides (OLP)-48: RQANFLGKIWPSHKGRPGNF (RL42 Gag434-453); OLP-2: GQLDRWEKIRLRPGGKKKYR (RL42 Gag11-30); OLP-15: VQNLQGQMVHQPISPRTLNA (RL42 Gag135-154) and OLP-16: HQPISPRTLNAWVKVVEEKA (RL42 Gag144-163) were dominant in HLA-A30-B13-C06-positive patients. A new epitope [HQPISPRTL (Gag144-152, HL9)] within OLP-15 and OLP-16 was identified. Results showed that strong cross-reactive responses to multiple immunodominant peptides were associated with better clinical outcomes. In addition, efficient cross-recognition of HL9 autologous variants developed in patients was associated with high CD4 T-cell counts. However, two patients who had developed mutations to their dominant responses during the follow-up experienced decrease in CD4 T-cell counts. It appears that Gag-specific T-cell responses against one or more unmutated epitopes or cross-recognition of autologous epitope variants contribute to slow disease progression in HLA-A30-B13-C06-positive patients.

conclusionWe conclude that a single 'appropriate' Gag-specific T-cell response appears to be sufficient to protect patients from disease progression. HLA-A30-B13-C06-positive individuals benefited from having a choice of numerous immunodominant gag epitopes for T cells to react. The study offers new insight for future design of T-cell-based HIV-1 vaccine.

Indexed as

HIV Long-Term SurvivorsAdultAsian PeopleCross ReactionsEnzyme-Linked Immunospot AssayFemalegag Gene Products, Human Immunodeficiency VirusHaplotypesHIV InfectionsHLA AntigensHumansImmunodominant EpitopesInterferon-gammaLongitudinal StudiesMaleMiddle Agedgag Gene Products, Human Immunodeficiency VirusHLA AntigensImmunodominant EpitopesInterferon-gamma

Identifiers

PMID25756195
PMCPMC4444423
OpenAlexW2000049931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.